Search
+
    SEARCHED FOR:

    HOFFMANN LA ROCHE

    Roche Vs Natco: Supreme Court clears decks for launch of Natco Pharma's Risdiplam generic in India

    The Supreme Court has allowed Natco Pharma to launch its generic version of the spinal muscular atrophy drug Risdiplam in India, dismissing F. Hoffmann-La Roche's appeal. The court upheld the Delhi High Court's decision, which prioritized public access to the life-saving medication at a significantly lower price.

    Roche moves SC against Natco’s launch of generic Risdiplam in India

    F. Hoffmann-La Roche AG has approached the Supreme Court. This follows a Delhi High Court decision permitting Natco Pharma to introduce a generic version of Risdiplam. Risdiplam treats spinal muscular atrophy. The High Court rejected Roche's plea to halt Natco's manufacturing. Natco plans to sell the drug at a significantly lower price.

    Delhi HC allows Natco Pharma to launch risdiplam, rejects Roche plea

    The Delhi High Court has permitted Natco Pharma to launch its affordable generic version of risdiplam, a crucial drug for spinal muscular atrophy. This decision overturns a previous stay, allowing Natco to offer the medication at a significantly lower price than Swiss multinational Roche's imported Evrysdi. Roche expressed disappointment, emphasizing the importance of patent protection for innovation.

    Delhi HC asks Natco Pharma to pause Risdiplam launch amid patent dispute

    The Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the patent for the drug, sought an injunction to prevent Natco from manufacturing it in India. The court highlighted the public interest in making the drug affordable.

    Supreme Court asks Zydus Lifesciences to approach Delhi HC over ban on selling breast cancer drug Sigrima

    The Supreme Court has instructed Zydus Lifesciences to approach the Delhi High Court. Zydus is seeking relief from an order that prevents the sale of its breast cancer drug, Sigrima. Swiss pharmaceutical giant, Roche, alleges that Sigrima is similar to its own cancer drug. Roche requested the court to prohibit Zydus from selling Sigrima.

    Delhi HC allows Zydus Lifesciences to sell breast cancer drug Sigrima

    The Delhi High Court division bench has allowed Zydus Lifesciences to sell its breast cancer drug Sigrima amidst accusations of it being similar to Roche's Perjeta. The court invalidated an earlier restraint order, noting no patent infringement by Zydus.

    The Economic Times
    BACK TO TOP